SCHAUMBURG, IL – Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched Bivalirudin for Injection in the United States as a therapeutic equivalent generic for Angiomax® for Injection (bivalirudin) approved by the U.S. Food and Drug Administration. Bivalirudin for Injection is indicated for use as an anticoagulant for use in patients undergoing percutaneous coronary intervention (PCI) including patients with heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome.
Avenacy’s injectable product contains 250 mg of bivalirudin as a lyophilized powder in a single-dose vial for reconstitution. In line with Avenacy’s mission to champion patient safety and streamline patient care, Bivalirudin for Injection will feature the Company’s highly differentiated packaging and labeling to support accurate medication selection.
Avenacy will begin shipping Bivalirudin for Injection to wholesale partners this week. The Company is supported by a global network of development and FDA-approved cGMP-certified contract manufacturing partners.
Bivalirudin for Injection had U.S. sales of approximately $25 million for the twelve months ending in June 2023.1
Please see link for Full Prescribing Information.
Angiomax® is a registered trademark of Sandoz, Inc.
